HALO

Halozyme Therapeutics, Inc. (HALO) ESG Analysis Analysis (2026)

Invetso Score: 6.3/10 — Balanced · Last Updated: 2026-10-01

Environmental

R&D intensity of 6.1% of revenue suggests a meaningful innovation footprint versus peers, but the metric alone does not indicate superior environmental stewardship.

The absence of disclosed FCF margin limits visibility into capital allocation for lower-carbon or resource-efficient initiatives, leaving HALO less transparent than better-disclosed peers.

High gross margin can support investment in cleaner processes and compliance systems, yet peers with explicit sustainability metrics still provide stronger environmental evidence.

No direct emissions, energy, or waste data were provided, so HALO’s environmental positioning remains harder to verify than peers with fuller ESG disclosure.

Social

Stock-based compensation at 3.8% of revenue indicates employee alignment, but peers with broader workforce metrics usually demonstrate stronger social disclosure.

R&D spending of 6.1% of revenue can support product quality and patient or customer outcomes, though the social benefit is less visible than in peer disclosures.

No workforce safety, turnover, diversity, or community-impact metrics were provided, which weakens comparability against peers with more complete social reporting.

The available data suggest some human-capital investment, but HALO remains only mid-pack versus peers because key social indicators are not disclosed.

Governance

Debt-to-equity of 9.8x indicates a more leveraged capital structure than many peers, which can constrain governance flexibility and heighten oversight demands.

Net debt to EBITDA of 2.8x is manageable, but peers with lower leverage typically face less balance-sheet pressure and simpler governance risk profiles.

Stock-based compensation at 3.8% of revenue is not excessive, yet peers with tighter dilution controls often show stronger capital-discipline governance.

The provided metrics do not include board independence, audit quality, or shareholder-rights data, leaving HALO’s governance assessment below best-disclosed peers.

Overall Score

HALO appears mid-pack versus peers overall, with some support from R&D intensity and compensation alignment, but limited ESG disclosure and elevated leverage cap the score.

Score Driver: Limited ESG Disclosure Combined With Elevated Leverage Versus Peers

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Halozyme Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →